RxDoctor Payments Data

Shahram Ravan, MD

Cardiology · Beverly Hills, CANPI 1073544417

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Amgen at 26.0% of the total.

$3,996in general payments, 2019–2025

Across 174 payments — averaging $22.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Jazz Pharmaceuticals Inc.$316
  • GSK$286
  • Novartis$277
  • Boehringer Ingelheim$266
  • AstraZeneca$246
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$3,996100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,996 in reported general payments places this provider in the 75th percentile of 156 cardiology providers in California.

See all cardiology providers in California

Medicare billing

Part B allowed, 2024
$136,103
Medicare patients
183
Services billed
1,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5017$122,006
EliquisApixaban27$36,218
Repatha SureclickEvolocumab11$13,581
SynthroidLevothyroxine Sodium32$2,521
Metoprolol Succinate127$1,703
Rosuvastatin Calcium78$956
Atorvastatin Calcium52$515
Lisinopril65$471
Amlodipine Besylate90$466
Losartan Potassium81$446
Amiodarone Hcl17$386
Tamsulosin Hcl35$328
Methylphenidate Hcl14$255
Olmesartan Medoxomil16$244
Metformin Hcl29$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Eliquis$165$158,22444 claims
AbbVieSynthroid$52$2,52132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 156 cardiology providers in California.

Other cardiology in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →